October 11, 2017 / 11:47 AM / a year ago

BRIEF-Moleculin announces strategic collaboration to develop immune stimulation drug

Oct 11 (Reuters) - Moleculin Biotech Inc:

* Moleculin announces strategic collaboration to develop immune stimulation drug

* Moleculin Biotech - ‍entered into an agreement to collaborate with University of Bergen to expand research on inhibition of brain metastasis by moleculin’s pre-clinical drug WP1066​

* Moleculin biotech - ‍Moleculin anticipates clinical trial for drug to be ready to begin by end of this year​

* Moleculin Biotech - investigational new drug ‍application to study WP1066 ‍in patients with glioblastoma and melanoma has been on hold pending responses to requests from FDA​

* Moleculin Biotech - ‍anticipates clinical trial on WP1066 to begin by end of the year. If FDA allows the IND application to proceed based on responses provided​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below